OncoSynergy Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.16M
- Investors
-
17
OncoSynergy General Information
Description
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies employ a transformative strategy based on the RMI (Resistance Mechanism Inhibitors) principle that inhibits several cancer-driving pathways simultaneously, enabling oncologists to provide durable outcomes and cures for patients.
Contact Information
Website
www.oncosynergy.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 850 Pacific Street
- Unit 1802
- Stamford, CT 06902
- United States
+1 (415) 000-0000
OncoSynergy Timeline
OncoSynergy Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 13-May-2022 | $6.16M | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 7. Later Stage VC | 08-Sep-2020 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 6. Grant | 24-Jan-2020 | 000 | 000.00 | Completed | Clinical Trials - General | |
| 5. Later Stage VC (Series A) | 14-May-2018 | 0000 | 000.00 | 0000 | Completed | Clinical Trials - General |
| 4. Accelerator/Incubator | 19-May-2017 | 000.00 | Completed | Clinical Trials - General | ||
| 3. Accelerator/Incubator | 000.00 | Completed | Clinical Trials - General | |||
| 2. Merger/Acquisition | 05-Apr-2016 | Cancelled | Clinical Trials - General | |||
| 1. Equity Crowdfunding | 28-Jun-2015 | $13.2M | $13.2M | Completed | Clinical Trials - General |
OncoSynergy Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
OncoSynergy Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies emplo
Drug Discovery
Stamford, CT
6
As of 2022
000.00
0000000000 0
000.00
000000
por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Zurich, Switzerland
00
As of 0000
000.00
000000 0
000000
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000000000000
South San Francisco, CA
000
As of 0000
00000
00000000
00000
Add Comparison
OncoSynergy Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Araris Biotech | Venture Capital-Backed | Zurich, Switzerland | 00 | 000.00 | 000000 0 | |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Schlieren, Switzerland | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
OncoSynergy Patents
OncoSynergy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018260887-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Abandoned | 26-Dec-2012 | 00000000000 | |
| EP-2938359-A4 | Anti- integrin beta1 antibody compositions and methods of use thereof | Withdrawn | 26-Dec-2012 | 00000000000 | 0 |
| JP-2016512487-A | Anti-integrin β1 antibody composition and method of use | Granted | 26-Dec-2012 | 00000000000 | 0 |
| EP-2938359-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Withdrawn | 26-Dec-2012 | 00000000000 | |
| US-20180312591-A1 | Anti-integrin beta-1 antibody compositions and methods of use thereof | Granted | 26-Dec-2012 | C07K16/2842 |
OncoSynergy Executive Team (4)
OncoSynergy Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Allen Salmasi Ph.D | Self | Chairman | 000 0000 |
| Amanda Hayward Ph.D | Connecticut Innovations | Board Member | 000 0000 |
| Colin Foster | Self | Board Member | 000 0000 |
| Hen Park Ph.D | OncoSynergy | Board Member | 000 0000 |
| Robert Dunkle | OncoSynergy | Board Member | 000 0000 |
OncoSynergy Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OncoSynergy Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Cancer Institute | Government | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Connecticut Innovations | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Korea Information & Communications Company | Corporation | Minority | 000 0000 | 000000 0 |
OncoSynergy Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 01-May-2013 | 0000000000 | Pharmaceuticals |